Aripiprazole

Summary

Aripiprazole (CHEMBL1112) is an approved small-molecule H1-receptor antagonist (ATC N05AX12) targeting HTR6, HTR7, and HTR1A; indicated across 31 conditions including autism and psychotic disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N05AX12
• Targets: 10 (HTR6, HTR7, HTR1A…)
• Indications: 31 conditions
• Clinical trials: 316
• Chemistry: 448.4 Da · C23H27Cl2N3O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1112
Name	Aripiprazole
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	60795
ChEBI	CHEBI:31236
ATC	N05AX12
Molecular formula	C23H27Cl2N3O2
Molecular weight	448.4
InChIKey	CEUORZQYGODEFX-UHFFFAOYSA-N

SMILES: C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl

IUPAC name: 7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-3,4-dihydro-1H-quinolin-2-one

ChEBI definition: An N-arylpiperazine that is piperazine substituted by a 4-[(2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)oxy]butyl group at position 1 and by a 2,3-dichlorophenyl group at position 4. It is an antipsychotic drug used for the treatment of Schizophrenia, and other mood disorders.

Pharmacological roles (ChEBI): H1-receptor antagonist, serotonergic agonist, second generation antipsychotic.

Other ChEBI roles (chemical / environmental): drug metabolite.

Also known as: Abilify, Abilify asimtufii, Abilify maintena, Abilify maintena kit, Abilify mycite, Abilify mycite kit, Aripiprazol, Aripiprazole, Aripiprazole accord, Aripiprazole sandoz, Aripiprazole zentiva, Aripiprex

Patent coverage: 6,490 distinct patent families (24,205 SureChEMBL compound mentions), from 6 matched compound structure(s). One matched structure accounts for 23,782 (98%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
HTR6	5-HT6 receptor	Antagonist	6.8	0.2%	P50406
HTR7	5-HT7 receptor	Partial agonist	7.8	0.8%	P34969
HTR1A	5-HT1A receptor	Partial agonist	8.2	0%	P08908
DRD2	D2 receptor	Partial agonist	7.42	0%	P14416
DRD4	D4 receptor	Antagonist	7.3	0%	P21917
HRH1	H1 receptor	Antagonist	7.5	0%	P35367
HTR1B	5-HT1B receptor	Full agonist	6.1	0.2%	P28222
HTR1D	5-HT1D receptor	Full agonist	7.2	0%	P28221
HTR2A	5-HT2A receptor	Partial agonist	8.1	0%	P28223
HTR2C	5-HT2C receptor	Partial agonist	7.6	0%	P28335

Broader ChEMBL bioactivity targets: 72 (assay-derived). Sample: Tyrosyl-DNA phosphodiesterase 1, Microtubule-associated protein tau, Nuclear receptor ROR-gamma, Inositol monophosphatase 1, 5-hydroxytryptamine receptor 2B, D(1B) dopamine receptor, Alpha-2A adrenergic receptor, Androgen receptor, Vasopressin V1a receptor, 5-hydroxytryptamine receptor 1B.

Bioactivity

ChEMBL activities: 355 potent at pChembl ≥ 5 of 371 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
DRD2	9.7	Ki	0.2	nM	CHEMBL_ACT_12652733
DRD2	9.52	Ki	0.3	nM	CHEMBL_ACT_24842598
DRD2	9.47	Ki	0.34	nM	CHEMBL_ACT_18891554
DRD2	9.47	Ki	0.34	nM	CHEMBL_ACT_25011687
DRD2	9.46	Ki	0.34	nM	CHEMBL_ACT_15644299
HTR2B	9.44	Ki	0.36	nM	CHEMBL_ACT_16624847
HTR2B	9.44	Ki	0.36	nM	CHEMBL_ACT_25630000
DRD2	9.42	Ki	0.38	nM	CHEMBL_ACT_18073322
DRD2	9.42	Ki	0.38	nM	CHEMBL_ACT_18216964
P19327	9.4	Ki	0.4	nM	CHEMBL_ACT_3128467
DRD2	9.35	Ki	0.45	nM	CHEMBL_ACT_14731996
DRD2	9.35	Ki	0.45	nM	CHEMBL_ACT_18042843
DRD2	9.32	Ki	0.48	nM	CHEMBL_ACT_15702093
DRD2	9.32	Ki	0.48	nM	CHEMBL_ACT_18049394
DRD2	9.28	Ki	0.53	nM	CHEMBL_ACT_18042788
DRD2	9.28	Ki	0.52	nM	CHEMBL_ACT_18073304
DRD2	9.28	Ki	0.52	nM	CHEMBL_ACT_18216922
DRD2	9.27	Ki	0.54	nM	CHEMBL_ACT_14731975
DRD2	9.16	Ki	0.69	nM	CHEMBL_ACT_23238228
DRD2	9.1	Ki	0.8	nM	CHEMBL_ACT_12627260
DRD2	9.1	Ki	0.8	nM	CHEMBL_ACT_15078827
DRD2	9.1	Ki	0.8	nM	CHEMBL_ACT_18653024
P61169	9.1	Ki	0.8	nM	CHEMBL_ACT_2248508
DRD3	9.1	Ki	0.8	nM	CHEMBL_ACT_25011692
HTR2A	9.1	Ki	0.8	nM	CHEMBL_ACT_29098213
P18901	9.1	Ki	0.8	nM	CHEMBL_ACT_3367638
HTR2A	9.1	Ki	0.8	nM	CHEMBL_ACT_6339207
DRD2	9	EC50	1	nM	CHEMBL_ACT_12089403
DRD3	9	Ki	1	nM	CHEMBL_ACT_15644305
DRD2	9	EC50	1	nM	CHEMBL_ACT_19114927

Target pathways

Aggregated over 10 target gene(s): HTR6, HTR7, HTR1A, DRD2, DRD4, HRH1, HTR1B, HTR1D, HTR2A, HTR2C.

Top Reactome pathways

13 total, by targets touching each:

Pathway	Targets	Genes
Signal Transduction	7	HTR1A, HTR1B, HTR1D, HTR2A, HTR2C, HTR6, HTR7
Signaling by GPCR	7	HTR1A, HTR1B, HTR1D, HTR2A, HTR2C, HTR6, HTR7
Class A/1 (Rhodopsin-like receptors)	7	HTR1A, HTR1B, HTR1D, HTR2A, HTR2C, HTR6, HTR7
Amine ligand-binding receptors	7	HTR1A, HTR1B, HTR1D, HTR2A, HTR2C, HTR6, HTR7
Serotonin receptors	7	HTR1A, HTR1B, HTR1D, HTR2A, HTR2C, HTR6, HTR7
GPCR ligand binding	7	HTR1A, HTR1B, HTR1D, HTR2A, HTR2C, HTR6, HTR7
GPCR downstream signalling	6	HTR1B, HTR1D, HTR2A, HTR2C, HTR6, HTR7
G alpha (q) signalling events	3	HRH1, HTR2A, HTR2C
G alpha (i) signalling events	3	DRD4, HTR1B, HTR1D
Dopamine receptors	2	DRD2, DRD4
G alpha (s) signalling events	2	HTR6, HTR7
Histamine receptors	1	HRH1
RHOBTB3 ATPase cycle	1	HTR7

Dominant GO biological processes

GO term	Targets
signal transduction	10
G protein-coupled receptor signaling pathway	10
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	9
chemical synaptic transmission	9
G protein-coupled serotonin receptor signaling pathway	6
intracellular calcium ion homeostasis	4
phospholipase C-activating serotonin receptor signaling pathway	4
adenylate cyclase-modulating G protein-coupled receptor signaling pathway	3
vasoconstriction	3
behavioral fear response	3
adenylate cyclase-inhibiting serotonin receptor signaling pathway	3
serotonin receptor signaling pathway	3
adult behavior	3
regulation of behavior	3
phospholipase C-activating G protein-coupled receptor signaling pathway	3

Indications & clinical

Indications

31 indications (11 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
autism	4	MONDO:0005260	EFO:0003758
psychotic disorder	4	MONDO:0005485	EFO:0005407
Tourette syndrome	4	MONDO:0007661	EFO:0004895
schizoaffective disorder	4	MONDO:0005487	EFO:0005411
major depressive disorder	4	MONDO:0002009	MONDO:0002009
depressive disorder	4	MONDO:0002050	MONDO:0002050
bipolar disorder	4	MONDO:0004985	EFO:0009963
post-traumatic stress disorder	3	MONDO:0005146	EFO:0001358
autism spectrum disorder	3	MONDO:0005258	EFO:0003756
postpartum depression	3	MONDO:0005929	EFO:0007453
anxiety	3	MONDO:0011918	EFO:0005230
dementia	3	MONDO:0001627	HP:0000726
pervasive developmental disorder	3	MONDO:0000594	MONDO:0000594
Alzheimer disease	3	MONDO:0004975	MONDO:0004975
alcohol abuse	3	MONDO:0002046	MONDO:0007079
anorexia nervosa	3	MONDO:0005351	MONDO:0005351
mental disorder	3	MONDO:0005084	EFO:0000677
tic disorder	3	MONDO:0002420	MONDO:0001074
attention deficit-hyperactivity disorder	2	MONDO:0007743	EFO:0003888
cocaine dependence	2	MONDO:0005186	EFO:0002610
obsessive-compulsive disorder	2	MONDO:0008114	EFO:0004242
fragile X syndrome	2	MONDO:0010383	MONDO:0010383
trichotillomania	2	MONDO:0013189	HP:0012167
methamphetamine dependence	1	MONDO:0005419	EFO:0004701

7 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 316.

Phase distribution

Phase	Trials
PHASE4	122
PHASE3	94
Not specified	48
PHASE2	24
PHASE1	18
PHASE2/PHASE3	6
PHASE1/PHASE2	3
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06433635	PHASE4	ACTIVE_NOT_RECRUITING	Sequential Multiple Assignment Randomized Trial for Bipolar Depression
NCT06501339	PHASE4	NOT_YET_RECRUITING	Maintenance Electroconvulsive Therapy (ECT) Versus Aripiprazole in Clozapine-resistant Schizophrenia
NCT06969755	PHASE4	RECRUITING	Biomarkers to Enhance Early Schizophrenia Treatment
NCT07011693	PHASE4	NOT_YET_RECRUITING	Switching Medication and Augmentation Strategies for SSRI-Resistant Adolescent Depression（SMART-I)
NCT07047651	PHASE4	ACTIVE_NOT_RECRUITING	Τhe Combination of Pharmacotherapy With RECOVERYTRSGR and RECOVERYTRSBDGR.
NCT07483294	PHASE4	RECRUITING	Cerebellum-based Imaging Neural Markers for Antipsychotic Response
NCT00044655	PHASE4	COMPLETED	Switching Medication to Treat Schizophrenia
NCT00080327	PHASE4	COMPLETED	Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia
NCT00082199	PHASE4	COMPLETED	Study of Aripiprazole in Subjects With Alcoholism
NCT00088049	PHASE4	COMPLETED	Study of Olanzapine vs. Aripiprazole in the Treatment of Schizophrenia
NCT00095810	PHASE4	COMPLETED	Aripiprazole in Patients With Psychosis Associated With Parkinson’s Disease
NCT00103571	PHASE4	COMPLETED	Olanzapine Versus Aripiprazole in the Treatment of Acutely Ill Patients With Schizophrenia
NCT00167817	PHASE4	COMPLETED	Effect of Switch to Aripiprazole on Health and Smoking Parameters in Patients With Schizophrenia: A Pilot Study
NCT00177008	PHASE4	COMPLETED	Aripiprazole for the Treatment of Schizophrenia With Co-Morbid Social Anxiety
NCT00181779	PHASE4	COMPLETED	Aripiprazole for the Treatment of Mania in Children and Adolescents With Bipolar Disorder
NCT00194038	PHASE4	COMPLETED	Aripiprazole in Late Life Bipolar Disorder
NCT00198198	PHASE4	COMPLETED	Aripiprazole Treatment of Bipolar Depression
NCT00205699	PHASE4	COMPLETED	Metabolic Effects of Antipsychotics in Children
NCT00208169	PHASE4	COMPLETED	Abilify Therapy for Reducing Comorbid Substance Abuse
NCT00220636	PHASE4	COMPLETED	Abilify as an Adjunctive Treatment for Refractory Depression
NCT00221962	PHASE4	COMPLETED	Study of Aripiprazole (Abilify) in Children With ADHD (Attention Deficit Hyperactivity Disorder)
NCT00222833	PHASE4	COMPLETED	The Effect of Switching to Aripiprazole on Heart Health in Overweight and Obese Patients With Schizophrenia
NCT00223496	PHASE4	COMPLETED	12- Week Open Label Treatment of Refractory Bipolar Depression
NCT00224822	PHASE4	COMPLETED	The Effects of Aripiprazole on Patients With Metabolic Syndrome
NCT00232687	PHASE4	COMPLETED	A Switch Study of BMS-337039 in Schizophrenic Out-patients
NCT00241176	PHASE4	COMPLETED	Open Label Trial of Aripiprazole in Children and Adolescents With Tourette’s Disorder
NCT00245206	PHASE4	COMPLETED	Side Effects of Newer Antipsychotics in Older Adults
NCT00250705	PHASE4	COMPLETED	Trial of Aripiprazole in the Treatment of CD in Adolescents
NCT00277212	PHASE4	COMPLETED	A Phase IV Study of the Safety and Efficacy of Aripiprazole in Combination With Lamotrigine in the Long-Term Maintenance Treatment of Patients With Bipolar I Disorder With A Recent Manic or Mixed Episode
NCT00299702	PHASE4	COMPLETED	Evaluation of Effectiveness of Risperdal® Consta® Compared to Abilify® Over a Two-year Period in Patients With Schizophrenia
NCT00300846	PHASE4	COMPLETED	A Study of Adjunctive Treatment of Aripiprazole in Schizophrenic Patients
NCT00304616	PHASE4	COMPLETED	SWitching to Abilify Trial (SWAT)
NCT00304655	PHASE4	COMPLETED	Acute Psychosis Treatment in the Long Term, Unitary Group Study (APLUS)
NCT00305370	PHASE4	COMPLETED	Aripiprazole Associated With Methylphenidate in Children and Adolescents With Bipolar Disorder and ADHD
NCT00320671	PHASE4	COMPLETED	Comparison of Aripiprazole and Risperidone for the Treatment of People With First-Episode Psychosis
NCT00325689	PHASE4	COMPLETED	Aripiprazole Used as Dual Therapy in the Treatement of Patients With Chronic Stable Schizophrenia or Schizoaffective Disorder.
NCT00328367	PHASE4	COMPLETED	Aripiprazole Augmentation for Clozapine-Treated Patients With Refractory Schizophrenia
NCT00329810	PHASE4	COMPLETED	Effect on Cognitive Function of a Treatment With Aripiprazole
NCT00330863	PHASE4	COMPLETED	Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy
NCT00345033	PHASE4	COMPLETED	Effectiveness of Aripiprazole for Improving Side Effects of Clozapine in the Treatment of People With Schizophrenia

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

PharmGKB dosing guidelines (1) — CPIC / DPWG genotype-guided dosing for this drug (drug × pharmacogene):

Guideline	Source	Gene(s)	Dosing	Recommendation
Annotation of DPWG Guideline for aripiprazole and CYP2D6	DPWG	CYP2D6	yes	yes

PharmGKB also curates 11 clinical and 105 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

776 molecules share ≥1 primary target. Top 60 by shared-target count:

Molecule	Source	Status	Shared targets
BREXPIPRAZOLE	ChEMBL + PubChem	Phase 4 (approved)	DRD2, DRD4, HRH1, HTR1A, HTR1B, HTR1D, HTR2A, HTR2C, HTR6, HTR7
DIHYDROERGOTAMINE	ChEMBL + PubChem	Phase 4 (approved)	DRD2, DRD4, HRH1, HTR1A, HTR1B, HTR1D, HTR2A, HTR2C, HTR6, HTR7
CARIPRAZINE	ChEMBL	Phase 4 (approved)	DRD2, DRD4, HRH1, HTR1A, HTR1B, HTR1D, HTR2A, HTR2C, HTR6, HTR7
IMIPRAMINE	ChEMBL	Phase 4 (approved)	DRD2, DRD4, HRH1, HTR1A, HTR1B, HTR1D, HTR2A, HTR2C, HTR6, HTR7
KETANSERIN	ChEMBL	Phase 4 (approved)	DRD2, DRD4, HRH1, HTR1A, HTR1B, HTR1D, HTR2A, HTR2C, HTR6, HTR7
NEFAZODONE	ChEMBL	Phase 4 (approved)	DRD2, DRD4, HRH1, HTR1A, HTR1B, HTR1D, HTR2A, HTR2C, HTR6, HTR7
RISPERIDONE	ChEMBL	Phase 4 (approved)	DRD2, DRD4, HRH1, HTR1A, HTR1B, HTR1D, HTR2A, HTR2C, HTR6, HTR7
CLOZAPINE	ChEMBL	Phase 4 (approved)	DRD2, DRD4, HRH1, HTR1A, HTR1B, HTR2A, HTR2C, HTR6, HTR7
MIANSERIN	ChEMBL	Phase 4 (approved)	DRD2, DRD4, HRH1, HTR1A, HTR1D, HTR2A, HTR2C, HTR6, HTR7
OLANZAPINE	ChEMBL	Phase 4 (approved)	DRD2, DRD4, HRH1, HTR1A, HTR1B, HTR2A, HTR2C, HTR6, HTR7
LYSERGIDE	ChEMBL	Phase 2	DRD2, DRD4, HRH1, HTR1A, HTR1D, HTR2A, HTR2C, HTR6, HTR7
PENFLURIDOL	ChEMBL	Phase 2	DRD2, DRD4, HRH1, HTR1A, HTR1D, HTR2A, HTR2C, HTR6, HTR7
RITANSERIN	ChEMBL	Phase 2	DRD2, DRD4, HRH1, HTR1A, HTR1B, HTR2A, HTR2C, HTR6, HTR7
PALIPERIDONE	ChEMBL + PubChem	Phase 4 (approved)	DRD2, DRD4, HRH1, HTR1B, HTR1D, HTR2A, HTR2C, HTR7
AMOXAPINE	ChEMBL	Phase 4 (approved)	DRD2, DRD4, HRH1, HTR1A, HTR2A, HTR2C, HTR6, HTR7
ASTEMIZOLE	ChEMBL	Phase 4 (approved)	DRD2, DRD4, HRH1, HTR1A, HTR2A, HTR2C, HTR6, HTR7
AZELASTINE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR1B, HTR1D, HTR2A, HTR2C, HTR6, HTR7
CHLORPROMAZINE	ChEMBL	Phase 4 (approved)	DRD2, DRD4, HRH1, HTR1A, HTR2A, HTR2C, HTR6, HTR7
CINACALCET	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR1A, HTR1D, HTR2A, HTR2C, HTR6, HTR7
DOXEPIN	ChEMBL	Phase 4 (approved)	DRD2, DRD4, HRH1, HTR1A, HTR2A, HTR2C, HTR6, HTR7
FLUPHENAZINE	ChEMBL	Phase 4 (approved)	DRD2, DRD4, HRH1, HTR1A, HTR2A, HTR2C, HTR6, HTR7
HALOPERIDOL	ChEMBL	Phase 4 (approved)	DRD2, DRD4, HRH1, HTR1A, HTR2A, HTR2C, HTR6, HTR7
LOXAPINE	ChEMBL	Phase 4 (approved)	DRD2, DRD4, HRH1, HTR1A, HTR2A, HTR2C, HTR6, HTR7
PROMAZINE	ChEMBL	Phase 4 (approved)	DRD2, DRD4, HRH1, HTR1A, HTR2A, HTR2C, HTR6, HTR7
QUETIAPINE	ChEMBL	Phase 4 (approved)	DRD2, DRD4, HRH1, HTR1A, HTR2A, HTR2C, HTR6, HTR7
SALMETEROL	ChEMBL	Phase 4 (approved)	DRD2, DRD4, HTR1A, HTR1B, HTR1D, HTR2A, HTR2C, HTR7
SERTINDOLE	ChEMBL	Phase 4 (approved)	DRD2, DRD4, HRH1, HTR1A, HTR1B, HTR2A, HTR2C, HTR6
TEGASEROD	ChEMBL	Phase 4 (approved)	DRD2, DRD4, HTR1A, HTR1D, HTR2A, HTR2C, HTR6, HTR7
THIORIDAZINE	ChEMBL	Phase 4 (approved)	DRD2, DRD4, HRH1, HTR1A, HTR2A, HTR2C, HTR6, HTR7
THIOTHIXENE	ChEMBL	Phase 4 (approved)	DRD2, DRD4, HRH1, HTR1A, HTR2A, HTR2C, HTR6, HTR7
VILAZODONE	ChEMBL	Phase 4 (approved)	DRD2, DRD4, HRH1, HTR1A, HTR1B, HTR1D, HTR6, HTR7
ZIPRASIDONE	ChEMBL	Phase 4 (approved)	DRD2, DRD4, HRH1, HTR1A, HTR2A, HTR2C, HTR6, HTR7
FANANSERIN	ChEMBL	Phase 2	DRD2, DRD4, HRH1, HTR1A, HTR2A, HTR2C, HTR6, HTR7
SPIPERONE	ChEMBL	Phase 2	DRD2, DRD4, HRH1, HTR1A, HTR2A, HTR2C, HTR6, HTR7
SPIRAMIDE	ChEMBL	Phase 2	DRD2, DRD4, HRH1, HTR1A, HTR1D, HTR2A, HTR6, HTR7
Pyrazinamide	PubChem	Approved	DRD2, DRD4, HRH1, HTR1A, HTR2A, HTR2C, HTR6, HTR7
DESLORATADINE	ChEMBL + PubChem	Phase 4 (approved)	DRD2, DRD4, HRH1, HTR1A, HTR2A, HTR2C, HTR6
PRAMIPEXOLE	ChEMBL + PubChem	Phase 4 (approved)	DRD2, DRD4, HRH1, HTR1A, HTR1B, HTR2A, HTR7
AMITRIPTYLINE	ChEMBL	Phase 4 (approved)	DRD2, DRD4, HRH1, HTR1A, HTR2A, HTR2C, HTR6
ASENAPINE	ChEMBL	Phase 4 (approved)	DRD2, DRD4, HRH1, HTR1A, HTR2A, HTR2C, HTR6
CARVEDILOL	ChEMBL	Phase 4 (approved)	DRD2, DRD4, HTR1A, HTR2A, HTR2C, HTR6, HTR7
CYPROHEPTADINE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR1A, HTR2A, HTR2C, HTR6, HTR7
EBASTINE	ChEMBL	Phase 4 (approved)	DRD2, DRD4, HRH1, HTR1A, HTR2A, HTR2C, HTR6
ERGOTAMINE	ChEMBL	Phase 4 (approved)	DRD2, HTR1A, HTR1B, HTR1D, HTR2A, HTR2C, HTR6
ILOPERIDONE	ChEMBL	Phase 4 (approved)	DRD2, DRD4, HRH1, HTR1A, HTR2A, HTR2C, HTR6
IPRINDOLE	ChEMBL	Phase 4 (approved)	DRD2, DRD4, HRH1, HTR1A, HTR2A, HTR2C, HTR6
KETOTIFEN	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR1B, HTR2A, HTR2C, HTR6, HTR7
METHYSERGIDE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR1A, HTR2A, HTR2C, HTR6, HTR7
PERGOLIDE	ChEMBL	Phase 4 (approved)	DRD2, DRD4, HRH1, HTR1A, HTR2A, HTR2C, HTR6
PIMOZIDE	ChEMBL	Phase 4 (approved)	DRD2, DRD4, HRH1, HTR1A, HTR2A, HTR2C, HTR6
PROCHLORPERAZINE	ChEMBL	Phase 4 (approved)	DRD2, DRD4, HRH1, HTR1A, HTR2A, HTR2C, HTR6
PROMETHAZINE	ChEMBL	Phase 4 (approved)	DRD2, DRD4, HRH1, HTR1A, HTR2A, HTR2C, HTR6
SILODOSIN	ChEMBL	Phase 4 (approved)	DRD2, DRD4, HRH1, HTR1A, HTR1B, HTR1D, HTR7
SUNITINIB	ChEMBL	Phase 4 (approved)	DRD2, DRD4, HRH1, HTR1A, HTR2A, HTR2C, HTR6
LATREPIRDINE	ChEMBL	Phase 3	DRD2, HRH1, HTR1D, HTR2A, HTR2C, HTR6, HTR7
LISURIDE	ChEMBL	Phase 3	DRD2, DRD4, HRH1, HTR1A, HTR2A, HTR2C, HTR6
SEROTONIN	ChEMBL	Phase 3	HTR1A, HTR1B, HTR1D, HTR2A, HTR2C, HTR6, HTR7
GSK163090	ChEMBL	Phase 2	DRD2, HTR1A, HTR1B, HTR1D, HTR2A, HTR2C, HTR7
MEBUFOTENIN	ChEMBL	Phase 2	HTR1A, HTR1B, HTR1D, HTR2A, HTR2C, HTR6, HTR7
METERGOLINE	ChEMBL	Phase 2	DRD2, HRH1, HTR1A, HTR2A, HTR2C, HTR6, HTR7